Vistagen Therapeutics, Inc. 8-K Filing
Ticker: VTGN · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Vistagen Therapeutics, Inc. (ticker: VTGN) to the SEC on Nov 4, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market).
How long is this filing?
Vistagen Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 552 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-11-04 16:10:25
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn-20251103.htm (8-K) — 25KB
- ex99120251103.htm (EX-99.1) — 17KB
- picture1.jpg (GRAPHIC) — 11KB
- 0001628280-25-048827.txt ( ) — 176KB
- vtgn-20251103.xsd (EX-101.SCH) — 2KB
- vtgn-20251103_lab.xml (EX-101.LAB) — 21KB
- vtgn-20251103_pre.xml (EX-101.PRE) — 12KB
- vtgn-20251103_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 3, 2025, Vistagen Therapeutics, Inc. (the " Company ") issued a press release to announce that the last patient has completed the randomized, double-blind, placebo-controlled public speaking challenge portion of the Company's PALISADE-3 Phase 3 clinical trial evaluating fasedienol for the acute treatment of social anxiety disorder. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. Disclaimer. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated November 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: November 4, 2025 By: /s/ Shawn K. Singh Shawn K. Singh President and Chief Executive Officer